Litcius/Paper detail

A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL

Kathrine T. Isaksen, Maria Adele Mastroianni, Marit Rinde, Leiv Sindre Rusten, Dlawer Abdulla Barzenje, Lloyd Frode Ramslien, Marit Slaaen, Marianne Brenn Jerm, Erlend B. Smeland, Siri Rostoft, Knut Liestøl, Marianne Brodtkorb, Harald Holte

2021Blood Advances31 citationsDOIOpen Access PDF

Abstract

Patients with diffuse large B-cell lymphoma (DLBCL) have a median age of 70 years. Yet, empirical knowledge about the treatment of older patients is limited because they are frequently excluded from clinical trials. We aimed to construct a simplified frailty score and examine survival and treatment-related mortality (TRM) according to frailty status and treatment intensity in an older real-world population with DLBCL. All patients aged ≥70 years diagnosed with DLBCL between 2006 and 2016 in southeastern Norway (N = 784) were included retrospectively and divided into training (n = 522) and validation (n = 262) cohorts. We constructed and validated a frailty score based on geriatric assessment variables and examined survival and TRM according to frailty status and treatment. The frailty score identified 3 frailty groups with distinct survival and TRM, independent of established prognostic factors (2-year overall survival [OS]: fit, 82%; unfit, 47%; frail, 14%; P < .001). For fit patients, full-dose R-CHOP (initial dosage >80%) was associated with better survival than attenuated R-CHOP ([R-miniCHOP]; 2-year OS: 86% vs 70%; P = .012), also in adjusted analyses. For unfit and frail patients, full-dose R-CHOP was not superior to R-miniCHOP, whereas an anthracycline-free regimen was associated with poorer survival in adjusted analyses. A simplified frailty score identified unfit and frail patients with a higher risk for death and TRM, which can aid treatment-intensity decisions in older patients with DLBCL. In this study, fit patients benefited from full-dose R-CHOP, whereas unfit and frail patients had no benefit from full-dose R-CHOP over R-miniCHOP. An online calculator for assessment of the frailty score is available at https://wide.shinyapps.io/app-frailty/.

Topics & Concepts

MedicineInternal medicineDiffuse large B-cell lymphomaRegimenPopulationCHOPOncologyLymphomaEnvironmental healthFrailty in Older AdultsLymphoma Diagnosis and TreatmentEsophageal Cancer Research and Treatment